PennyStockPayCheck.com Rss

Featured Posts

Richemont chairman Johann Rupert to take 'grey gap... Billionaire 62-year-old to take 12 months off from Cartier and Montblanc luxury goods groupRichemont's chairman and founder Johann Rupert is to take a year off from September, leaving management of the...

Read more

Cambodia: aftermath of fatal shoe factory collapse... Workers clear rubble following the collapse of a shoe factory in Kampong Speu, Cambodia, on Thursday

Read more

Spate of recent shock departures by 50-something CEOs While the rising financial rewards of running a modern multinational have been well publicised, executive recruiters say the pressures of the job have also been ratcheted upOn approaching his 60th birthday...

Read more

UK Uncut loses legal challenge over Goldman Sachs tax... While judge agreed the deal was 'not a glorious episode in the history of the Revenue', he ruled it was not unlawfulCampaign group UK Uncut Legal Action has lost its high court challenge over the legality...

Read more

Eurozone crisis live: Japan's strong growth figures... PM Shinzo Abe's stimulus package could generate feelgood factor needed to end two decades of stagnant growthPhillip Inman

Read more

Active Biotech’s partner Ipsen initiates a proof-of-concept study with tasquinimod in additional cancer indications

Posted by admin | Posted on 19-10-2012

Category : Stocks

Tags: , , , , , , , , , , , , ,

LUND, SWEDEN–(Marketwire – Oct 19, 2012) – Active Biotech (NASDAQ OMX NORDIC: ACTI) today
announces that its partner Ipsen (Euronext: IPN; ADR: IPSEY, read press
release
here) will initiate a new phase II, proof-of-concept clinical trial
with
tasquinimod in a so-called umbrella study evaluating the compound in
four
different tumor types.

Read more from the original source: Active Biotech’s partner Ipsen initiates a proof-of-concept study with tasquinimod in additional cancer indications

Post to Twitter

Dr. Sohila Zadran Examines Metabolism at the Neuronal-Tumor Interface

Posted by admin | Posted on 25-09-2012

Category : World News

Tags: , , , , , , , , ,

LOS ANGELES, CA–(Marketwire – Sep 25, 2012) – Gliomablastoma multiform (GBM) is the most fatal form of all brain cancers in humans. Response to current therapies remains extremely poor, with dismal survival statistics. Recently, calpains, a large conserved family of cysteine proteases regulated by calcium, have been implicated in GBM tumor pathogenesis. Calpain activity is implicated in several physiological processes, including cytoskeletal remodeling, cellular signaling and apoptosis. The calpain isoforms, calpain1 and calpain2, are ubiquitous and abundant in the central nervous system (CNS).

More: Dr. Sohila Zadran Examines Metabolism at the Neuronal-Tumor Interface

Post to Twitter

Nanostart AG (NASRY: OTC Link) | Nanostart-holding MagForce enters into preclinical research agreement to investigate NanoTherm® therapy in the gastrointestinal cancer field in the USA

Posted by admin | Posted on 22-06-2012

Category : Stocks

Tags: , , , , , , , , ,

  • Goal is to achieve preclinical proof-of-concept in pancreatic and liver cancer
  • First important milestone to set up a clinical development program with Key Opinion Leaders of the Mayo Clinic and throughout the US
  • A previous pilot study conducted at the Charit

    Post to Twitter

Venezuela Chavez needs more cancer treatment

Posted by admin | Posted on 05-03-2012

Category : World News

Tags: , , , , , , , ,

Ahead of October presidential poll, the country’s president insists there was no metastasis after the removal of tumor.

The rest is here: Venezuela Chavez needs more cancer treatment

Post to Twitter